Study of FGF19 protein and liver cancer outlook
Part of Cancer, Digestive system clinical trials.
This study looks at whether a certain protein (called FGF19) in your liver cancer tissue can help predict how the disease will progress. The findings might help doctors better understand and plan treatment for people with advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need a diagnosis of intermediate or advanced liver cancer (a type called hepatocellular carcinoma).
- You must have a stored tissue sample from a previous biopsy or surgery of your liver cancer.
- Your doctor expects you to live longer than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
This trial tests two new targeted drugs (ABSK-011 and ABSK043) for people with advanced liver cancer whose tumors have high levels of the FGF19 protein and who have already tried at least one other treatment.
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.